Trial Profile
Study of incidence and risk factors for ibrutinib associated atrial fibrillation
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Aug 2016
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary)
- Indications Chronic lymphocytic leukaemia; Mantle-cell lymphoma
- Focus Adverse reactions
- 03 Aug 2016 New trial record
- 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology